Eric Donnenfeld, MD
Ophthalmology · Garden City, NYNPI 1891790770
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $998,867 of the $1,422,478 with a category attached, or 70.2%. It is spread thinly across 42 manufacturers, the largest accounting for just 20.8%. Among ophthalmology clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 954 payments — averaging $1491.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson Surgical Vision, Inc.$295K
- Alcon$238K
- Tarsus Pharmaceuticals, Inc.$147K
- Bausch & Lomb Americas Inc.$131K
- Omeros Corporation$104K
- Glaukos Corporation$94K
- plus $413K from 36 others
Across 66 payments — averaging $20,664 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Johnson & Johnson Surgical Vision, Inc.$730K
- Shire North American Group Inc$258K
- Ocular Therapeutix, Inc.$148K
- Omeros Corporation$50K
- Bausch & Lomb Americas Inc.$48K
- Alcon Research LLC$35K
- plus $95K from 5 others
Across 14 payments — averaging $500.09 each. An ownership or investment interest held by the physician or an immediate family member.
- Lensar, Inc.$7K
- Eyepoint US, Inc.$0
- Tearoptix, Inc.$0
- Rapid Pathogen Screening, Inc.$0
What the payments were for
- Consulting fees$998,86770%
- Speaking & faculty fees$182,23313%
- Grants$12,0491%
- Travel & lodging$13,0281%
- Food & beverage$32,0222%
- Education$4,6160%
- Gifts$10,1241%
- Other$169,53912%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Hydrus Microstent$170,645
- OMIDRIA$105,990
- Compact Intuitiv$97,801
- INTRALASE FS FEMTOSEC LASER$97,801
- IFS ADVANCED FEMTOSEC LASER$96,713
- XIIDRA$85,227
- MIEBO$56,264
- iStent inject Trabecular Micro-Bypass Stent System$50,286
- iStent Trabecular Micro-Bypass Stent System$50,162
- CATALYS SYSTEM$49,323
- Tecnis 1-piece IOL$40,628
- Tecnis 3-piece IOL$38,969
- Tecnis Symphony IOL$38,969
- Tecnis Symphony Toric IOL$38,969
- ILUX$37,915
- Catalys Laser System$25,382
- COMPACT INTUITIV Phacofragmentation System$24,513
- Lacrifill$24,257
- iStent inject W$20,757
- iStent$20,465
How this compares
$1,422,478 in reported general payments places this provider in the 95th percentile of 1,587 ophthalmology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XdemvyLotilaner | 44 | $77,987 |
| RestasisCyclosporine | 60 | $72,493 |
| Bromfenac Sodium | 722 | $65,991 |
| MieboPerfluorohexyloctane/Pf | 30 | $44,800 |
| XiidraLifitegrast | 38 | $40,188 |
| Prednisolone Acetate | 1,159 | $36,903 |
| ProlensaBromfenac Sodium | 110 | $36,902 |
| Ofloxacin | 1,120 | $13,445 |
| Cyclosporine | 17 | $11,144 |
| Loteprednol Etabonate | 70 | $10,314 |
| EysuvisLoteprednol Etabonate | 19 | $9,295 |
| LumiganBimatoprost | 13 | $7,367 |
| Tobramycin-DexamethasoneTobramycin/Dexamethasone | 68 | $3,063 |
| Difluprednate | 22 | $2,979 |
| MoxifloxacinMoxifloxacin Hcl | 119 | $2,247 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bausch & Lomb Americas Inc.Miebo, Xiidra | $131,447 | $84,98868 claims |
| AbbVieRestasis, Lumigan | $16,284 | $79,86073 claims |
| Tarsus Pharmaceuticals, Inc.Xdemvy | $146,652 | $77,98744 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa, Loteprednol Etabonate | $4,756 | $47,216180 claims |
| Kala Pharmaceuticals, Inc.Eysuvis | $13,973 | $9,29519 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,587 ophthalmology providers in New York.
Other ophthalmology in Garden City
- David RubaltelliBrooklyn$8.9M
- Nathan RadcliffeNew York$2.1M
- Richard SpaideNew York$1.7M
- Marguerite McDonaldOceanside$893K
- Joshua YoungNew York$814K
- David KleinmanRochester$730K
- Jonathan JonischGreat Neck$726K
- Joseph PanarelliNew York$541K
- Eric RosenbergNew York$434K
- Michael CooneyNew York$398K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.